BeiGeneius webinars

Explore educational content in hemato-oncology delivered by international experts. Browse previous webinar recordings on-demand, including navigable, chapterized content.
Back to all webinars

First-line treatment of patients with CLL: The end of chemotherapy?

Francesc Bosch, Stephan Stilgenbauer and Alessandra Tedeschi discuss the first-line treatment of patients with CLL, including the role of first-line chemotherapy and selecting continuous vs time-limited targeted therapy.

Duration: 01:30:57 View full-length webinar
Video
22 Nov 2022
CLL
BTKi
BCL2i
Speakers

Alessandra Tedeschi

Stephan Stilgenbauer

Francesc Bosch

First-line treatment for patients with CLL

Alessandra Tedeschi

Duration: 31:57
Webinar10_Thumbnail-3
Fast-forward to:
When to treat patients with CLL?
6391d6d46b83cb0f874bf899
Early intervention vs. observation
6391dae3130b0f0f79793fd4
Treatment selection
6391db9c6b83cb0f874bf8ba
Covalent BTKis
6391de64b37d640f826ccbc5
Venetoclax and obinutuzumab
6391e62e130b0f0f7979404e
Is there still a role for FCR in first-line CLL?
6391e89725be170f7afccfd1
Treatment of patients with del(17p)/TP53mut
6391ea82130b0f0f79794070
Conclusions: First-line treatment of CLL
6391ebc56b83cb0f874bf956

Time-limited vs. continuous targeted therapy in CLL

Stephan Stilgenbauer

Duration: 13:54
Webinar10_Thumbnail-4
Fast-forward to:
First-line BTKi-based therapy vs. CIT
6391f4ef6b83cb0f874bf96c
BTKi therapy for del(17p) / TP53mut
6391f8e425be170f7afcd020
Ibrutinib AEs and treatment discontinuation
6391fa306b83cb0f874bf98c
Next-generation BTKis
6391fb11130b0f0f797940c2
Venetoclax-based regimens
6391fbecb37d640f826ccca4
Patient characteristics, disease parameters and treatment goals
6391fec325be170f7afcd070
Conclusions: Time-limited vs. continuous targeted therapy
639200166b83cb0f874bf9cd

Panel discussion & audience Q&A

Francesc Bosch,

Stephan Stilgenbauer,

Alessandra Tedeschi

Duration: 41:44
Webinar10_Thumbnail-5
Fast-forward to:
Is fitness irrelevant for CLL patients with del(17p)?
639200cf6b83cb0f874bf9d4
Challenges with venetoclax and obinutuzumab
639201816b83cb0f874bf9db
What is the role of transplant in patients with del(17p)/TP53mut/complex karyotype after targeted therapy?
639202146b83cb0f874bf9ea
How do you manage switching a patient from ibrutinib to a next-generation BTKi?
639202696b83cb0f874bf9f4
Management of immunosuppression and infections in the COVID-19 era
639202ec25be170f7afcd0b1
How effective is retreatment for patients who relapse on fixed-duration venetoclax regimens?
63920345b37d640f826ccd02
Sequencing of therapies
6392038f130b0f0f7979413b
The role of ibrutinib + venetoclax
639204086b83cb0f874bfa0e
Back to all webinars